Menu
Not yet recruiting NCT07749547

Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica

No phase Interventional Polymyalgia Rheumatica (PMR)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Movement Pattern Training (MoveTrain), Usual Care.
Who it may be relevant to
Registry conditions: Polymyalgia Rheumatica (PMR). Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica: a Feasibility Randomized Clinical Trial

Overview

Polymyalgia rheumatica (PMR) is a condition that causes joint pain and stiffness, making it hard for people to do everyday tasks. Movement pattern training is a special, personalized rehabilitation program that aims to reduce pain by improving how people move during their daily activities. The investigators plan to test if it's possible to conduct a detailed study to find out how effective Movement pattern training is for people with PMR. The investigators will look at whether it helps them perform activities they want to do, reduce their use of certain medications, and strengthen their muscles. The investigators will also gather feedback from patients about their experience with Movement pattern training. This study will help us understand if carrying out a larger study on Movement pattern training's effectiveness is practical.

Interventions

  • Behavioral Movement Pattern Training (MoveTrain)
    6 individualized treatment sessions over 10 weeks * Motivational interviewing to determine personal goals and strengthen motivation and commitment to change * Activity-specific training to practice modified motion during patient-specific tasks, defined as activities reported by each patient as pain-provoking * Home exercise program 3 times/week consisting of activities or exercises assigned in the supervised sessions * Patient's independence and adherence in performing home exercise program wil
  • Other Usual Care
    * Basic education about polymyalgia rheumatica, benefits of physical activity * Patients will be encouraged to participate in physical activity as tolerated * Medication as prescribed by their physician

Primary outcome measures

  • Number of potential participants accessed. [Time frame: 7 months]
  • Percent of eligible participants who were willing to be randomized [Time frame: 7 months]
Secondary outcome measures (4)
  • Preliminary estimates of change in polymyalgia rheumatica impact scale (PMR-IS) [Time frame: From enrollment to the end of treatment at 10 weeks]
  • Preliminary estimates of change in physical activity [Time frame: From enrollment to the end of treatment at 10 weeks]
  • Preliminary estimates of change in cumulative glucocorticoid dose [Time frame: From enrollment to the end of treatment at 10 weeks]
  • Preliminary estimates of change in muscle strength [Time frame: From enrollment to the end of treatment at 10 weeks]

Eligibility criteria

Inclusion criteria

  • Patient reports a diagnosis or flare of polymyalgia rheumatica (PMR) < 5 months before the screening contact
  • Diagnosis or flare of PMR according to the European League against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria as follows (must satisfy all criteria)10:
  • Age ≥50 years at time of diagnosis
  • Presence of bilateral shoulder pain
  • Elevated acute phase reactants C-reactive protein (CRP) >10 milligram/Liter and/or Erythrocyte Sedimentation Rate (ESR) >30 millimeters/hour\*
  • A score ≥4 at the time of diagnosis based on the following (without ultrasound):
  • Duration of morning stiffness >45 minutes: 2 points
  • Hip pain or limited range of motion: 1 point
  • Seronegative for rheumatoid factor and anti-cyclic citrullinated peptide: 2 points
  • Absence of other joint involvement: 1 point
  • Initiated pharmacological treatment
  • Able to give informed consent
  • Physician's clearance to participate in physical activity

Exclusion criteria

  • Diagnosis of fibromyalgia, neuropathic muscular disease, complex regional pain syndrome, or small fiber neuropathy
  • planned major surgical procedure during the study
  • Current active uncontrolled infection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Other

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Harris-Hayes M, Steger-May K, Bove AM, Foster SN, Mueller MJ, Clohisy JC, Fitzgerald GK. Movement pattern training compared with standard strengthening and flexibility among patients with hip-related groin pain: results of a pilot multicentre randomised clinical trial. BMJ Open Sport Exerc Med. 2020 Mar 23;6(1):e000707. doi: 10.1136/bmjsem-2019-000707. eCollection 2020. PMID 32518674
  • Mackie SL, Twohig H, Neill LM, Harrison E, Shea B, Black RJ, Kermani TA, Merkel PA, Mallen CD, Buttgereit F, Mukhtyar C, Simon LS, Hill CL; OMERACT PMR Working Group. The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. J Rheumatol. 2017 Oct;44(10):1515-1521. doi: 10.3899/jrheum.161109. Epub 2017 Aug 1. PMID 28765246
  • O'Brien AV, Muller S, Liddle J, Thomas MJ, Mallen CD. Physiotherapy for the Management of Polymyalgia Rheumatica: Results From a UK Cross-Sectional Survey. Musculoskeletal Care. 2025 Sep;23(3):e70155. doi: 10.1002/msc.70155. PMID 40619692
  • Harris-Hayes M, Czuppon S, Van Dillen LR, Steger-May K, Sahrmann S, Schootman M, Salsich GB, Clohisy JC, Mueller MJ. Movement-Pattern Training to Improve Function in People With Chronic Hip Joint Pain: A Feasibility Randomized Clinical Trial. J Orthop Sports Phys Ther. 2016 Jun;46(6):452-61. doi: 10.2519/jospt.2016.6279. Epub 2016 Apr 26. PMID 27117727
  • Twohig H, Mitchell C, Mallen CD, Muller S. Development and psychometric evaluation of the PMR-Impact Scale: a new patient reported outcome measure for polymyalgia rheumatica. Rheumatology (Oxford). 2023 Feb 1;62(2):758-765. doi: 10.1093/rheumatology/keac317. PMID 35639659
  • Twohig H, Mitchell C, Mallen C, Adebajo A, Mathers N. "I suddenly felt I'd aged": a qualitative study of patient experiences of polymyalgia rheumatica (PMR). Patient Educ Couns. 2015 May;98(5):645-50. doi: 10.1016/j.pec.2014.12.013. Epub 2015 Jan 15. PMID 25638304
  • Taylor CB, Coffey T, Berra K, Iaffaldano R, Casey K, Haskell WL. Seven-day activity and self-report compared to a direct measure of physical activity. Am J Epidemiol. 1984 Dec;120(6):818-24. doi: 10.1093/oxfordjournals.aje.a113954. PMID 6507425
  • Slade SC, Dionne CE, Underwood M, Buchbinder R. Consensus on Exercise Reporting Template (CERT): Explanation and Elaboration Statement. Br J Sports Med. 2016 Dec;50(23):1428-1437. doi: 10.1136/bjsports-2016-096651. Epub 2016 Oct 5. PMID 27707738

Identifiers

NCT: NCT07749547 · 202602100

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗